Keynote 775 - Len/Pem, 2022

Question 1

Study question for Keynote 775?

Answer 1

Standard treatment for adv endometrial cancer after failure of plat-based chemo is unclear; safety and efficacy s/p Keynote 146

Question 2

Study design of Keynote 775?

Answer 2

1:1 len/pem vs chemo (doxil or more taxel)
Lenvatinib - 20 mg qd; pembro 200 mg q 3 weeks

Question 3

Inclusion criteria of Keynote 775?

Answer 3

Measurable disease, adv, rec or mets endeometrial ca, ALL histologies (not CS or sarcoma); no VEGF or PD-1 prior treatment

Question 4

Results of Keynote 775?

Answer 4

n=827 (697 pMMR); RCT len/pem vs chemo
PFS - pMMR 6.6 vs 3.8 mo (chemo)
OS - pMMR 17.4 vs 12 mo (chemo)

90% with AEs - HTN, diarrhea (50%), nausea (50%)

*exploratory MMRd analysis